Invention Grant
- Patent Title: Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
-
Application No.: US15761262Application Date: 2016-09-20
-
Publication No.: US10647771B2Publication Date: 2020-05-12
- Inventor: Jennifer H. Yearley , Linda Liang , Michael Eric Bigler , Christopher John Gibson
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Letitia Walker; Laura M. Ginkel
- International Application: PCT/US2016/052569 WO 20160920
- International Announcement: WO2017/053250 WO 20170330
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61P35/00 ; G01N33/574

Abstract:
The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
Public/Granted literature
- US20180258171A1 ANTIBODY THAT BINDS TO HUMAN PROGRAMMED DEATH LIGAND 2 (PD-L2) AND USES THEREOF Public/Granted day:2018-09-13
Information query